SCHEMBL21487952

SCHEMBL21487952

O=C(N[C@H](CC1CCCCC1)C(=O)N1C[C@H](O)C[C@H]1C(=O)O)c1ccc2ccccc2c1

nearest known ligand 0.63

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
HTRA1 Q92743 20/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21487954 1.00 HTRA1 (0.63) HTRA1
SCHEMBL24012373 0.92 HTRA1 (0.62) HTRA1
SCHEMBL29750937 0.90 HTRA1 (0.62) HTRA1
SCHEMBL21506057 0.90 HTRA1 (0.62) HTRA1
SCHEMBL19744616 0.88 HTRA1 (0.76) HTRA1
SCHEMBL30334966 0.88 HTRA1 (0.76) HTRA1
SCHEMBL19744612 0.88 HTRA1 (0.76) HTRA1
SCHEMBL19745295 0.88 HTRA1 (0.76) HTRA1
SCHEMBL19745297 0.88 HTRA1 (0.76) HTRA1
SCHEMBL28979589 0.88 HTRA1 (0.76) HTRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4257191-A2 HETEROCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2023-10-11 EP disclosed
EP-3472149-B1 HETEROCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2023-08-30 EP disclosed
US-20220267306-A1 HETEROCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2022-08-25 US disclosed
US-11377439-B2 Heterocyclic prolinamide derivatives Orion Ophthalmology LLC (US) 2022-07-05 US disclosed
US-11377439-B2 Heterocyclic prolinamide derivatives Orion Ophthalmology LLC (US) 2022-07-05 US disclosed
CN-114685453-A Heterocyclic prolinamide derivatives 奥瑞恩眼科有限责任公司 2022-07-01 CN disclosed
CN-109476637-B Heterocyclic prolinamide derivatives 奥瑞恩眼科有限责任公司 2022-02-01 CN disclosed
US-20190322645-A1 HETEROCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2019-10-24 US disclosed
US-20190322645-A1 HETEROCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2019-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190322645-A1 HETEROCYCLIC PROLINAMIDE DERIVATIVES HTRA1, ALDH1A2, HTRA2 HTRA1 1/4885
US-20220267306-A1 HETEROCYCLIC PROLINAMIDE DERIVATIVES HTRA1, ALDH1A2, HTRA2 HTRA1 1/4885
US-11377439-B2 Heterocyclic prolinamide derivatives HTRA1, ALDH1A2, HTRA2 HTRA1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.